381 related articles for article (PubMed ID: 28760226)
21. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
22. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus.
Tejedor Jorge A
Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224
[TBL] [Abstract][Full Text] [Related]
23. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.
Cai X; Yang W; Gao X; Chen Y; Zhou L; Zhang S; Han X; Ji L
Obesity (Silver Spring); 2018 Jan; 26(1):70-80. PubMed ID: 29165885
[TBL] [Abstract][Full Text] [Related]
24. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
Tikkanen I; Chilton R; Johansen OE
Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):81-6. PubMed ID: 26808705
[TBL] [Abstract][Full Text] [Related]
25. [Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type].
Prázný M; Slíva J
Vnitr Lek; 2015 Feb; 61(2):175-8. PubMed ID: 25813264
[TBL] [Abstract][Full Text] [Related]
26. SGLT2 inhibitors: new reports.
Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
[TBL] [Abstract][Full Text] [Related]
27. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
Misra M
J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
[TBL] [Abstract][Full Text] [Related]
28. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
29. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Dailey GE
Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
[TBL] [Abstract][Full Text] [Related]
30. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P
Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
[TBL] [Abstract][Full Text] [Related]
31. SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms.
Filippatos TD; Tsimihodimos V; Liamis G; Elisaf MS
Diabetes Metab Syndr; 2018; 12(1):59-63. PubMed ID: 28826578
[TBL] [Abstract][Full Text] [Related]
32. [Type 2 diabetes mellitus: new treatments].
Ascaso JF
Med Clin (Barc); 2014 Aug; 143(3):117-23. PubMed ID: 23937815
[TBL] [Abstract][Full Text] [Related]
33. SGLT2 inhibitors: molecular design and potential differences in effect.
Isaji M
Kidney Int Suppl; 2011 Mar; (120):S14-9. PubMed ID: 21358697
[TBL] [Abstract][Full Text] [Related]
34. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
[TBL] [Abstract][Full Text] [Related]
35. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
36. [Clinical and practical management of sodium-glucose cotransporter type 2 inhibitors in patients with chronic kidney disease].
Castillo Moraga MJ; Turégano-Yedro M; Pallarés-Carratala V
Semergen; 2023 Jun; 49 Suppl 1():102020. PubMed ID: 37355299
[TBL] [Abstract][Full Text] [Related]
37. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β-cell function and reduction of insulin resistance.
Kaneto H; Obata A; Kimura T; Shimoda M; Okauchi S; Shimo N; Matsuoka TA; Kaku K
J Diabetes; 2017 Mar; 9(3):219-225. PubMed ID: 27754601
[TBL] [Abstract][Full Text] [Related]
38. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.
Scheen AJ
Clin Pharmacokinet; 2014 Apr; 53(4):295-304. PubMed ID: 24420910
[TBL] [Abstract][Full Text] [Related]
39. Sodium-glucose cotransporter inhibitors for diabetes.
Isaji M
Curr Opin Investig Drugs; 2007 Apr; 8(4):285-92. PubMed ID: 17458177
[TBL] [Abstract][Full Text] [Related]
40. New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Dalama B; Mesa J
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1088-1097. PubMed ID: 27687335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
